Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EDSA | PRESS-RELEASE | bearish | 7/10 | Edesa Biotech priced a $25M underwritten public offering of common shares and warrants at $5.50 per unit, with an additi | Aug 19, 2026 |
| MRNA | ANALYST-UPGRADE | mixed | 1/10 | William Blair double-upgraded MRNA from Market Perform to Outperform on August 19, 2026, a rare two-step move that signa | Aug 19, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, and a net profit of $38M vs a loss of $2M in H1 202 | Aug 19, 2026 |
| HALO | CLUSTER | neutral | 2/10 | CEO Helen Torley executed a large-scale option exercise and open-market sale program over Aug 17-19, 2026, selling a tot | Aug 19, 2026 |
| ADPT | CLUSTER | bearish | 5/10 | CEO Chad Robins and Director Peter Neupert executed large-scale option exercises and open-market sales totaling ~$18M ov | Aug 19, 2026 |
| REPL | CLUSTER | mixed | 6/10 | Replimune insiders show a mixed cluster: Baker Bros. (10% owner) bought $1.52M in the public offering at $12.06, while t | Aug 19, 2026 |
| AAPG | PRESS-RELEASE | neutral | 5/10 | Ascentage Pharma reported H1 2026 revenue of $44.5M, up 29% YoY, driven by product sales growth of 33%. However, the net | Aug 19, 2026 |
| REVB | 8-K | neutral | 3/10 | Revelation Biosciences granted restricted stock awards to CEO James Rolke (208,076 shares) and CFO Chester Zygmont (208, | Aug 19, 2026 |
| PDSB | 8-K | neutral | 3/10 | PDS Biotechnology Corp disclosed the resignation of CFO Lars Boesgaard, effective September 12, 2026, to pursue other pr | Aug 19, 2026 |
| BAK | 6-K | bearish | 6/10 | Braskem S.A. filed a 6-K announcing the replacement of its auditor, KPMG, with Deloitte Touche Tohmatsu for fiscal years | Aug 19, 2026 |
| HURA | 8-K | neutral | 3/10 | TuHURA Biosciences filed an 8-K reporting that stockholders approved the issuance of 1,878,287 common shares to Parkview | Aug 19, 2026 |
| TANH | 6-K | neutral | 2/10 | Tantech Holdings filed a 6-K reporting the resignation of two independent directors (Shudong Wang and Mengqi Liao) effec | Aug 19, 2026 |
| CNEY | 6-K | neutral | 4/10 | CN Energy Group announced via a 6-K filing that its Canadian subsidiary's oil well project in Cold Lake, Alberta has com | Aug 19, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two insiders at Arcutis Biotherapeutics sold a combined $299K in open-market sales over a week, with Director Welgus How | Aug 19, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech reported Q2 2026 adjusted EPS of -$0.11, missing consensus of -$0.08 by 30.2%. H1 2026 total adjusted revenue f | Aug 19, 2026 |
| MEDP | 144 | neutral | 3/10 | Director Fred B. Davenport Jr. filed a Form 144 on August 19, 2026, indicating intent to sell 7,283 shares of Medpace Ho | Aug 19, 2026 |
| TARS | 144 | neutral | 3/10 | Aziz Mottiwala, a former officer of Tarsus Pharmaceuticals, filed a Form 144 notice of intent to sell 53,043 shares of c | Aug 19, 2026 |
| AZN | COURT-RULING | neutral | 1/10 | The U.S. District Court for the District of Maryland denied plaintiff Monique Richards Smith's motion to alter or amend | Aug 19, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings (ELAB) announced a 1-for-10 reverse stock split effective August 21, 2026, reducing outstanding shares fro | Aug 19, 2026 |
| ETON | 144 | bearish | 5/10 | CEO Sean Brynjelsen filed a Form 144 to sell 100,000 shares of Eton Pharmaceuticals common stock, valued at approximatel | Aug 19, 2026 |
| ASND | ANALYST-UPGRADE | bullish | 4/10 | BMO Capital initiated coverage on Ascendis Pharma A/S (ASND) at Outperform with a $319 price target, representing 28% up | Aug 19, 2026 |
| KPRX | 8-K | bullish | 5/10 | Kiora Pharmaceuticals has entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical (CKD) for the d | Aug 19, 2026 |
| GLMD | 6-K | neutral | 4/10 | Galmed Pharmaceuticals announced successful first-in-human proof-of-concept results for Colospan's novel intraoperative | Aug 19, 2026 |
| SAFX | S-1 | bearish | 8/10 | XCF Global filed an S-1 registration statement to register 212,770,019 shares of Class A common stock for resale by sell | Aug 19, 2026 |
| TELO | DEFA14A | neutral | 2/10 | Telomir Pharmaceuticals filed a DEFA14A supplement to its 2026 proxy statement, correcting the Audit Committee membershi | Aug 19, 2026 |
| MNOV | 8-K | neutral | 2/10 | MediciNova entered into new executive employment agreements with CEO Yuichi Iwaki and CMO Kazuko Matsuda, formalizing ba | Aug 19, 2026 |
| ALNY | COURT-RULING | neutral | 4/10 | A Markman claim construction ruling in a patent case brought by the University of Texas against Alnylam over its drug ON | Aug 19, 2026 |
| CMMB | 6-K | neutral | 6/10 | Chemomab reported Q2 2026 financial results and provided a corporate update centered on the proposed all-stock merger wi | Aug 19, 2026 |
| NSRX | 6-K | neutral | 3/10 | Nasus Pharma announced the resignation of CFO Eyal Rubin, effective September 18, 2026, to pursue an opportunity outside | Aug 19, 2026 |
| SCNI | 6-K | bearish | 6/10 | Scinai Immunotherapeutics announced a 1-for-10 ADS ratio change effective August 21, 2026, to increase the per-ADS tradi | Aug 19, 2026 |